Hemagen Diagnostics Overview
Valuation check: HMGN's ROE is 25.51%, above the Healthcare sector average of -75.59%.
Get informed when a big investor buys or sells
+ Follow25.51%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, HMGN shows a ROE of 25.51%. That is above the Healthcare sector average of -75.59%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about -75.59%. Hemagen Diagnostics is at 25.51%, which is higher that average. That is roughly 133.7% above the sector mean. Use the comparison chart on this page to see how HMGN stacks up against individual peers as well.
Check the historical chart to see whether HMGN's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Hemagen Diagnostics with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Hemagen Diagnostics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 25.51%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about -75.59%, while HMGN is at 25.51%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
